The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
Open accessAbstract
BACKGROUND: Plasma triglyceride levels are heritable and are correlated with the risk of coronary heart disease. Sequencing of the protein-coding regions of the human genome (the exome) has the potential to identify rare mutations that have a large effect on phenotype. METHODS: We sequenced the protein-coding regions of 18,666 genes in each of 3734 participants of European or African ancestry in the Exome Sequencing Project. We conducted tests to determine whether rare mutations in coding sequence, individually or in aggregate within a gene, were associated with plasma triglyceride levels. For mutations associated with triglyceride levels, we subsequently evaluated their association with the risk of coronary heart disease in 110,970 persons. RESULTS: An aggregate of rare mutations in the gene encoding apolipoprotein C3 (APOC3) was associated with lower plasma triglyceride levels. Among the four mutations that drove this result, three were loss-of-function mutations: a nonsense mutation (R19X) and two splice-site mutations (IVS2+1G→A and IVS3+1G→T). The fourth was a missense mutation (A43T). Approximately 1 in 150 persons in the study was a heterozygous carrier of at least one of these four mutations. Triglyceride levels in the carriers were 39% lower than levels in noncarriers (P<1×10(-20)), and circulating levels of APOC3 in carriers were 46% lower than levels in noncarriers (P=8×10(-10)). The risk of coronary heart disease among 498 carriers of any rare APOC3 mutation was 40% lower than the risk among 110,472 noncarriers (odds ratio, 0.60; 95% confidence interval, 0.47 to 0.75; P=4×10(-6)). CONCLUSIONS: Rare mutations that disrupt APOC3 function were associated with lower levels of plasma triglycerides and APOC3. Carriers of these mutations were found to have a reduced risk of coronary heart disease. (Funded by the National Heart, Lung, and Blood Institute and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Observational cohorts demonstrate that higher TG and remnant cholesterol predict cardiovascular events independently of LDL-C, while Mendelian randomization analyses confirm a causal relationship between lifelong TRL elevation and ASCVD.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [60]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrary, loss-of-function mutations of the ApoC-III are associated with a lower risk of CVD [170–172].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [172]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apolipoprotein C-III is a central regulator of triglyceride metabolism that limits the clearance of triglyceride-rich lipoproteins through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoprotein remnants. 6-8”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, loss-of-function mutations in APOC3, which encodes apolipoprotein C-III, result in significantly lower plasma TG levels and confer a 40–50% lower risk of ischemic cardiovascular events [25].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss-of-function variants in APOC3 confer protection against coronary artery disease, independent of LDL cholesterol levels [60, 112]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [60]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Individuals with loss-of-function mutations in APOC-III exhibit significantly reduced levels of triglycerides and remnant cholesterol, along with a nearly 40% reduction in ASCVD risk [32, 33].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Individuals with genetic loss-of-function mutations in the APOC3 gene exhibit markedly lower TG levels and reduced incidence of CAD, highlighting apoC-III as a compelling therapeutic target for HTG and associated complications [25, 29, 43].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, with genetic studies supporting the role of several novel therapeutic targets (eg, apo C-III and ANGPTL3) in atherosclerosis, ongoing clinical trials using RNA interference therapy (antisense oligonucleotides and small interfering RNAs) have the potential to further inform our understanding of the triglyceride-based atherosclerotic pathways (120,121).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [120]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Two large randomized controlled trials (RCTs) evaluating the efficacy of extended-release niacin vs placebo on background statin therapy in individuals with established ASCVD did not demonstrate a reduction in vascular events”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“and is a genetically validated target to reduce ASCVD risk.8–10,64–66”
From Clinical review on triglycerides (2020) · cites this paper as [64]
In the citing paper
“ApoCIII has been identified as a potentially important new risk factor. 104-106”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [106]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD. 106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [106]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD.106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [106]
In the citing paper
“defects in genes controlling TG metabolism, including APOC3, ANGPTL3 and ANGPTL4 that have been linked to reduced TG and are associated with reduced coronary calcification25 or reduced CVD risk.26-30”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,457
Multi-Ethnic Study of Atherosclerosis: Objectives and Design
Bild, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf113 · Cited by 3,942
The Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652
Robust relationship inference in genome-wide association studies
Manichaikul, A., Mychaleckyj, J. C., Rich, S. S., Daly, K., Sale, M., & Chen, W.-M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq559 · Cited by 3,541
THE ATHEROSCLEROSIS RISK IN COMMUNIT (ARIC) STUDY: DESIGN AND OBJECTIVES
THE ARIC INVESTIGATORS (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115184 · Cited by 3,510
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Flagged first, then by citations
1 of the 66 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Taylor HA, 2005, Ethn Dis, 15, S4
Cited by
Sorted by citations
Items 501–600 of 1,001
Lee, J. H., Oh, H.-K., Choi, B. S., Lee, H. H., Lee, K. J., Kim, U. G., Lee, J., Lee, H.-R., Lee, G. S., Ahn, S. J., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.08.002 · Cited by 19
Gurevitz, C., & Rosenson, R. S. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae388 · Cited by 19
Mooser, V., & Currat, C. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.14033 · Cited by 21
Impaired postprandial lipemic response in chronic kidney disease
Saland, J. M., Satlin, L. M., Zalsos-Johnson, J., Cremers, S., & Ginsberg, H. N. (2016) · Kidney International · doi:10.1016/j.kint.2016.02.031 · Cited by 19
Apoprotein C-III: A review of its clinical implications
Jin, J., Guo, Y., & Li, J. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.06.016 · Cited by 21
Wiesner, P., & Watson, K. E. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.03.004 · Cited by 21
Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
Reiner, Ž. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0343 · Cited by 19
Jansen, H., Lieb, W., & Schunkert, H. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6640-y · Cited by 19
Colombo, M., Looker, H. C., Farran, B., Agakov, F. V., Brosnan, M. J., Welsh, P. I., Sattar, N. A., Livingstone, S. J., Durrington, P. N., Betteridge, D. J., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.05.014 · Cited by 16
Cannabis effects on lipoproteins
Lazarte, J., & Hegele, R. A. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000575 · Cited by 18
Soto, L. G. D. L. P., Gutierrez-Uribe, J. A., Sharma, A. K., & Ramírez‐Jiménez, A. K. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.035 · Cited by 19
Dyslipidaemia of diabetes and the intestine
TOMKIN, G. H. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i7.970 · Cited by 18
Novel therapies for severe dyslipidemia originating from human genetics
Gaudet, D. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000281 · Cited by 18
Girelli, D., Piubelli, C., Martinelli, N., Corrocher, R., & Olivieri, O. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.03.019 · Cited by 18
Jia, X., Liu, J., Mehta, A., Ballantyne, C. M., & Virani, S. S. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07082-x · Cited by 18
Triglyceride-Rich Lipoproteins
Kockx, M., & Kritharides, L. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.008 · Cited by 20
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
Ward, N. C., Chan, D. C., & Watts, G. F. (2022) · BioDrugs · doi:10.1007/s40259-022-00520-2 · Cited by 18
Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1114 · Cited by 19
Feingold, K. R. (2017) · Europe PMC (PubMed Central) · Cited by 18
Sigfrids, F. J., Stechemesser, L., Dahlström, E. H., Forsblom, C. M., Harjutsalo, V., Weitgasser, R., Taskinen, M., Groop, P., & the FinnDiane Study Group (2021) · Journal of Internal Medicine · doi:10.1111/joim.13412 · Cited by 17
An Amish founder population reveals rare-population genetic determinants of the human lipidome
Montasser, M. E., Aslibekyan, S. W., Srinivasasainagendra, V., Tiwari, H. K., Patki, A., Bagheri, M., Kind, T., Barupal, D. K., Fan, S., Perry, J. A., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03291-2 · Cited by 18
Ruotsalainen, S., Surakka, I. L., Mars, N., Karjalainen, J. M., Kurki, M., Kanai, M., Krebs, K., Graham, S. E., Mishra, P. P., Mishra, B. H., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03552-0 · Cited by 21
Zahger, D., Schwartz, G. G., Du, W., Szarek, M. J., Bhatt, D. L., Bittner, V., Budaj, A., Díaz, R., Goodman, S. G., Jukema, J. W., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.035 · Cited by 18
Pokharel, Y., Sun, W., Polfus, L. M., Folsom, A. R., HEISS, G. M., Sharrett, A. R., Boerwinkle, E., Ballantyne, C. M., & Hoogeveen, R. C. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.033 · Cited by 17
Koch, M., Furtado, J. D., Jiang, Z. G., Gray, B. E., Cai, T., Sacks, F. M., Tjønneland, A. M., Overvad, K., & Jensen, M. K. (2017) · Journal of Lipid Research · doi:10.1194/jlr.p073288 · Cited by 17
Methods for the Analysis and Interpretation for Rare Variants Associated with Complex Traits
Weissenkampen, J. D., Jiang, Y., Eckert, S., Jiang, B., Li, B., & Liu, D. J. (2019) · Current Protocols in Human Genetics · doi:10.1002/cphg.83 · Cited by 20
Investigating Coronary Artery Disease methylome through targeted bisulfite sequencing
Ghose, S., Ghosh, S., Tanwar, V. S., Tolani, P., Kutum, R., Sharma, A., Bhardwaj, N., Vellarikkal, S. K., Verma, A., Jayarajan, R., et al. (2019) · Gene · doi:10.1016/j.gene.2019.144107 · Cited by 18
Trinder, M., & Brunham, L. R. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000737 · Cited by 17
Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle
Valladolid‐Acebes, I., Berggren, P., & Juntti‐Berggren, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020932 · Cited by 16
Milonas, D., & Τζιόμαλος, Κ. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1582028 · Cited by 17
Patel, A. P., & Natarajan, P. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz032 · Cited by 18
Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes
Tomlinson, B., Chan, P., & Lam, C. W. K. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1750949 · Cited by 20
HDL-associated apoCIII plays an independent role in predicting postprandial hypertriglyceridemia
Zhang, T., Tang, X., Mao, L., Chen, J., Kuang, J., Guo, X., Xu, D., Peng, D., & Yu, B. (2020) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2020.02.004 · Cited by 17
Association Analysis and Meta-Analysis of Multi-Allelic Variants for Large-Scale Sequence Data
Jiang, Y., Chen, S., Wang, X., Liu, M., Iacono, W. G., Hewitt, J. K., Hokanson, J. E., Krauter, K. S., Laakso, M., Li, K. W., et al. (2020) · Genes · doi:10.3390/genes11050586 · Cited by 18
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention
Quispe, R., Sweeney, T. E., Varma, B., Agarwala, A., & Michos, E. D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01052-4 · Cited by 18
Li, B., Zhou, X. J., Wang, W., Gao, Z., Yan, L., Qin, G., Tang, X., Wan, Q., Chen, L., Luo, Z., et al. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13362 · Cited by 16
Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis
Pintó, X., Fanlo‐Maresma, M., Esteve, V., Millán, J., Blanco, A., Blasco, M., Díaz-Díaz, J. L., Rodríguez, Á. D., Mangas, A., Pascual, V., et al. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.02.001 · Cited by 18
An overview of persistent chylomicronemia: much more than meets the eye
Larouche, M., Watts, G. F., Ballantyne, C. M., & Gaudet, D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000903 · Cited by 17
Human proteoforms as new targets for clinical mass spectrometry protein tests
Nedelkov, D. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1362337 · Cited by 16
Effects of n-3 fatty acid treatment on monocyte phenotypes in humans with hypertriglyceridemia
Perrard, X. D., Lian, Z., Bobotas, G., Dicklin, M. R., Maki, K. C., & Wu, H. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.08.011 · Cited by 16
Primary genetic disorders affecting high density lipoprotein (HDL)
Kosmas, C. E., Silverio, D., Sourlas, A., Garcia, F., Montan, P. D., & Guzman, E. (2018) · Drugs in Context · doi:10.7573/dic.212546 · Cited by 17
Shetty, S. K., Walzem, R. L., & Davies, B. S. J. (2020) · Journal of Lipid Research · doi:10.1194/jlr.d119000388 · Cited by 18
Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients
Wang, T., Xu, J., Fu, L., & Li, L. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13508 · Cited by 17
Katzmann, J. L., Werner, C. M., Stojaković, T., März, W., Scharnagl, H., & Laufs, U. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01293-9 · Cited by 16
Silbernagel, G., Scharnagl, H., Kleber, M. E., Hoffmann, M. M., Delgado, G., Stojaković, T., Gary, T., Zeng, L., Ritsch, A., Zewinger, S., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.08.017 · Cited by 16
Read, R. W., Schlauch, K. A., Lombardi, V. C., Cirulli, E. T., Washington, N. L., Lu, J. T., & Grzymski, J. J. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.639418 · Cited by 16
Wang, J.-S., Chiang, H., Wang, Y.-C., Yeh, H., Ting, I., Liang, C., Wang, M.-C., Lin, C., Hsiao, C.-T., Shen, M., et al. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.05.006 · Cited by 17
Genetics of coronary artery disease – A clinician's perspective
Manda, S. V., Reddy, S., Naik, A., & Naik, S. R. (2014) · Indian Heart Journal · doi:10.1016/j.ihj.2014.12.008 · Cited by 15
National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning
Lauer, M. S., Kiley, J. P., Mockrin, S. C., Mensah, G. A., Hoots, W. K., Patel, Y., Cook, N. L., Patterson, A. P., & Gibbons, G. H. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.005 · Cited by 16
The Genetics of Ischemic Heart Disease: From Current Knowledge to Clinical Implications
Elosúa, R., & Sayols-Baixeras, S. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.02.046 · Cited by 16
Joint Associations of APOC3 and LDL-C–Lowering Variants With the Risk of Coronary Heart Disease
Wang, W., Li, R. P., Song, Z., Huang, N., Huang, T., Hua, X., & Tang, Y.-D. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0195 · Cited by 16
Wang, J., Sun, Q., An, Y., Liu, J., Leng, S., & Wang, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.951635 · Cited by 15
Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia
Hooper, A. J., Bell, D. A., & Burnett, J. R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2408369 · Cited by 16
Bergmark, B. A., Marston, N., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Kang, Y. M., Murphy, S. A., Zhang, S. M., Lu, M. T., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.02.022 · Cited by 15
Common and Rare Variant Association Study for Plasma Lipids and Coronary Artery Disease
Tada, H., Kawashiri, M., Konno, T., Yamagishi, M., & Hayashi, K. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.31393 · Cited by 15
Wedervang‐Resell, K., Friis, S., Lonning, V., Smelror, R. E., Johannessen, C. H., Agartz, I., Ulven, S. M., Holven, K. B., Andreassen, O. A., & Myhre, A. M. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.11.039 · Cited by 15
Shaik, A., & Rosenson, R. S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07168-0 · Cited by 15
Sekimoto, T., Koba, S., Mori, H., Arai, T., Matsukawa, N., Sakai, R., Yokota, Y., Sato, S., Tanaka, H., Masaki, R., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.04.008 · Cited by 15
Triglyceride Treatment in the Age of Cholesterol Reduction
Agrawal, N., Corradi, P. F., Gumaste, N., & Goldberg, I. J. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.08.003 · Cited by 15
Maraninchi, M., Padilla, N., Béliard, S., Berthet, B., Nogueira, J. P., Dupont-Roussel, J., Mancini, J., Corroller, A. B., Dubois, N., Grangeot, R., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.02.012 · Cited by 16
Baum, S. J., & Scholz, K. P. (2019) · Clinical Cardiology · doi:10.1002/clc.23220 · Cited by 15
Loss-of-function tolerance of enhancers in the human genome
Xu, D., Gökçümen, Ö., & Khurana, E. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1008663 · Cited by 14
Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
Jia, X., Koh, S., Al Rifai, M., Blumenthal, R. S., & Virani, S. S. (2020) · Vascular Health and Risk Management · doi:10.2147/vhrm.s210149 · Cited by 14
Human genetic insights into lipoproteins and risk of cardiometabolic disease
Stitziel, N. O. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000389 · Cited by 14
Targeting RNA to lower triglycerides: long strides from short molecules
Qamar, A., Libby, P., & Bhatt, D. L. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz321 · Cited by 14
Marston, N., Bergmark, B. A., Prohaska, T. A., Moura, F. A., Zimerman, A., Alexander, V. J., Kang, Y. M., Weinland, J., Ran, X., Murphy, S. A., et al. (2026) · Circulation · doi:10.1161/circulationaha.126.080012 · Cited by 18
Lipoprotein Assessment in the twenty-first Century
Lucero, D., Wolska, A. T., Aligabi, Z., Turecamo, S. E., & Remaley, A. T. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.009 · Cited by 16
How to Handle Elevated Triglycerides: Life after PROMINENT
Pirillo, A., & Catapano, A. L. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01175-2 · Cited by 15
Human Genetics of Atherothrombotic Disease and its Risk Factors
Rader, D. J. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305492 · Cited by 14
A genome-wide study of lipid response to fenofibrate in Caucasians
Irvin, M. R., Rotroff, D. M., Aslibekyan, S. W., Zhi, D., Hidalgo, B., Motsinger‐Reif, A. A., Marvel, S. W., Srinivasasainagendra, V., Claas, S. A., Buse, J. B., et al. (2016) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000219 · Cited by 14
Kjellqvist, S., Klose, C. D., Surma, M. A., Hindy, G., Mollet, I. G., Johansson, A., Chavaux, P., Gottfries, J., Simons, K., Melander, O., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004503 · Cited by 13
Yamazaki, A., Ohkawa, R., Yamagata, Y., Horiuchi, Y., Lai, S.-J., Kameda, T., Ichimura, N., Tohda, S., & Tozuka, M. (2020) · Biological Chemistry · doi:10.1515/hsz-2020-0288 · Cited by 14
Distribution of seven ApoC-III glycoforms in plasma, VLDL, IDL, LDL and HDL of healthy subjects
Rodríguez, M. M., Rehues, P., Iranzo, V., Mora, J. D., Balsells, C., Guardiola, M., & Ribalta, J. (2021) · Journal of Proteomics · doi:10.1016/j.jprot.2021.104398 · Cited by 14
The genetic basis of sudden death in young people – Cardiac and non-cardiac
Li, F., Yin, P., & Xu, Z. (2021) · Gene · doi:10.1016/j.gene.2021.146067 · Cited by 14
Kastelein, J. J. P., Hallén, J., Vige, R., Fraser, D. A., Zhou, R., Hustvedt, S. O., Orloff, D. G., & Bays, H. E. (2016) · Cardiology · doi:10.1159/000445047 · Cited by 14
Effect of Hypertriglyceridemia on Beta Cell Mass and Function in ApoC3 Transgenic Mice
Liu, Y., Cheng, X., Zhang, T., Lee, S., Yamauchi, J., Xiao, X., Gittes, G. K., Qu, S., Jiang, C., & Dong, H. H. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.707885 · Cited by 14
Key differences between apoC-III regulation and expression in intestine and liver
West, G., Rodia, C. N., Li, D., Johnson, Z. K., Dong, H., & Kohan, A. B. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.116 · Cited by 17
Musunuru, K., Arora, P. K., Cooke, J. P., Ferguson, J. F., Hershberger, R. E., Hickey, K. T., Lee, J., Lima, J. A. C., Loscalzo, J., Pereira, N. L., et al. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/hcg.0000000000000046 · Cited by 14
Florentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 14
Olivieri, O., Speziali, G., Castagna, A., Pattini, P., Udali, S., Pizzolo, F., Liesinger, L., Gindlhuber, J., Tomin, T., Schittmayer, M., et al. (2020) · Journal of Nutrition · doi:10.1093/jn/nxaa202 · Cited by 15
Reversal of hypertriglyceridemia in diabetic BTBR ob/ob mice does not prevent nephropathy
Attie, A., Schueler, K., Keller, M. P., Mitok, K. A., Simonett, S. P., Hudkins, K. L., Mehrotra, K., Graham, M. J., Lee, R. G., & Alpers, C. E. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00592-8 · Cited by 14
Zeng, B., Li, R., Hu, Y., Hu, B., Zhao, Q., Liu, H., Yuan, P., & Wang, Y. (2015) · Gene · doi:10.1016/j.gene.2015.10.021 · Cited by 14
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease
Tsimikas, S. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01345-4 · Cited by 16
Drug Discovery for Coronary Artery Disease
Wan, Q., Qian, S., Yonghu, H., Zhang, Y., Peng, Z., Li, Q., Shu, B., Zhu, L., & Wang, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_8 · Cited by 13
Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk
Farnier, M. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0743-8 · Cited by 14
Bagdade, J. D., Barter, P. J., Quiroga, C., & Alaupovic, P. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.02.049 · Cited by 13
Wang, M., Wang, R., Li, L., Yan, Y., Jia, S., Jiang, H., & Du, Z. (2021) · Food & Function · doi:10.1039/d1fo01849c · Cited by 13
Li, X., Wang, L., Wang, L., Feng, Z., & Peng, C.-J. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s338090 · Cited by 13
Apolipoprotein C3 Is Downregulated in Patients With Inflammatory Bowel Disease
Hernández-Camba, A., Palau, M. C., Ramos, L., de Armas‐Rillo, L., Vela, M., Arranz, L., González-Gay, M. Á., & Ferraz‐Amaro, I. (2022) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000500 · Cited by 14
Rehues, P., Girona, J., Guardiola, M., Plana, N., Scicali, R., Piro, S., Muñiz-Grijalvo, O., Díaz-Díaz, J. L., Recasens, L., Pinyol, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032319 · Cited by 12
Mszar, R., Bart, S., Sakers, A. P., Soffer, D. E., & Karalis, D. G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041382 · Cited by 14
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia
Larouche, M., Khoury, É., Brisson, D., & Gaudet, D. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01179-y · Cited by 14
Li, S., Zhao, X., Zhang, Y., Zhu, C., Guo, Y., Wu, N., Xu, R., Qing, P., Gao, Y., Sun, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12471 · Cited by 13
Smith, M. R., Glicksberg, B. S., Li, L., Chen, R., Morishita, H., & Dudley, J. T. (2017) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789813235533_0007 · Cited by 14
Pek, S. L. T., Sum, C. F., Yeoh, L. Y., Lee, S. B. M., Tang, W. E., Lim, S. C., & Subramaniam, T. (2017) · Metabolism · doi:10.1016/j.metabol.2017.03.016 · Cited by 13
Lee, S. J., Mahankali, M., Bitar, A., Zou, H., Chao, E., Nguyen, H., González, J., Caballero, D., Hull, M. V., Wang, D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05163-w · Cited by 15
Obesity and Ischemic Heart Disease
McPherson, R. (2015) · Circulation Research · doi:10.1161/circresaha.115.305826 · Cited by 12
Genetic Variations, Triglycerides, and Atherosclerotic Disease
Tada, H., & Kawashiri, M. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed102 · Cited by 13
Ren, Z., Zhou, J., Yang, D., Guo, Y., Zhang, J., Xu, J., & Chen, Y. E. (2026) · Cells · doi:10.3390/cells15020134 · Cited by 13
Li, B., Zhou, X. J., Liu, Y., Zhang, Y., & Mu, Y. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64146 · Cited by 12
Metadata
- Authors
- The TG and HDL Working Group of the Exome Sequencing Project, N. H.
- Corresponding author
- The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-03
- Volume
- 371
- Issue
- 1
- Pages
- 22-31
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4180269
- OpenAlex
- W2170009139
- Semantic Scholar
- b3c2b9d4976782980ff38a64e223209866004dcc
- Cited by
- 1,071
- References
- 66
- Citations by year
- 2026: 52 · 2025: 73 · 2024: 48 · 2023: 56 · 2022: 75 · 2021: 93 · 2020: 110 · 2019: 90 · 2018: 81 · 2017: 113 · 2016: 132 · 2015: 107 · 2014: 41
- FWCI
- 89.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- Funders
- U.S. Department of Agriculture
- Massachusetts General Hospital (R01HL107816)
- University of Wisconsin-Milwaukee
- George Washington University
- University of Washington
- Donovan Family Foundation
- University of Ottawa
- Norges Teknisk-Naturvitenskapelige Universitet
- Queen Mary University of London
- Wellcome Trust
- Deutsches Zentrum für Herz-Kreislaufforschung
- Università degli Studi di Milano
- University of Texas Health Science Center at Houston
- Broad Institute
- Russell and Diana Hawkins Family Foundation
- National Institute for Health and Care Research (NF-SI-0611-10170)
- British Heart Foundation
- University of Leicester
- University of Oxford
- University of Leeds
- Fondation Leducq (T32HL007208)
- Lunds Universitet
- Hjärt-Lungfonden
- King Abdulaziz University
- Universität zu Lübeck
- Umeå Universitet
- Technische Universität München
- Università degli Studi di Verona
- Rheinische Friedrich-Wilhelms-Universität Bonn
- Novo Nordisk Fonden (NNF14OC0009819, NNF13OC0005339, NNF14OC0011049)
- Regione Emilia-Romagna
- National Institutes of Health (1rc2hl103010-01)
- School of Medicine, Stanford University
- University of North Carolina at Chapel Hill
- Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai
- Canadian Institutes of Health Research
- Medical Research Council
- Barts and The London School of Medicine and Dentistry
- Helmholtz Zentrum München
- National Institute on Aging (P30AG010129, U01AG049505)
- National Heart, Lung, and Blood Institute (HL 102923, RC2HL102925, HL-102924, K08HL114642, RC2HL102926, RC2HL102923, RC2HL-103010, HL 103010, RC2HL102924, R01HL107816, T32HL007208, R01HL109946)
- National Cancer Institute (R01CA082659)
- National Institute of Neurological Disorders and Stroke (R01NS017950)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein C-III, loss-of-function mutations, plasma triglycerides, coronary artery disease, rare variants, splice site mutation, nonsense mutation, missense mutations, genetic risk, European ancestry, African ancestry
- MeSH terms
- Coronary Disease, Genotype, Heterozygote, Humans, Liver, Mutation, Risk Factors, Triglycerides, Sequence Analysis, DNA, Black People, White People, Apolipoprotein C-III, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
